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NCORONARY-Coronary
CRT-162
Impella® and Tandem Heart® for Circulatory Support in Refractory Cardiogenic Shock
Guillermo Andres Cortes, Kevin Platt, Ryan Kobayashi, Ray Matthews,
Anilkumar Mehra, Michael Gaglia, David Shavelle, Leonardo Clavijo
University of Southern California, Los Angeles, CA
Background: Previous studies demonstrate that in patients with cardiogenic shock the
Impella® (Abiomed, Danvers, MA) and Tandem Heart® (CardiacAssist, Pittsburg,
PA) percutaneous left ventricular hemodynamic support devices improve cardiac index,
systemic blood pressure and mixed venous oxygen saturation. These devices are
expensive, survival data in this patient population is missing and comparisons between
devices are lacking.
Study Objective: Compare clinical and procedural characteristics, outcomes and
complications in patients with refractory cardiogenic shock (RCS) treated with the TH
and IMP for hemodynamic support.
Methods: Baseline demographics, clinical characteristics, procedural information and
hospital outcomes were investigated from January 2008 to June 2013 in patients
treated with either IMP or TH at Keck Medical Center of USC and LAC-USC
Medical Center.
Results: A total of 83 patients had TH or IMP for circulatory support; 20 patients
had device implantation for RCS (12 TH and 8 IMP). Mean age was 54.116.4,
80% of patients were male, 45% smokers, 35% diabetic and 20% CRI. Ischemic
cardiomyopathy was the etiology of RCS in 55% of patients. Ejection fraction
averaged 2112%. IMP patients were older (669 vs. 4615, p¼0.004). The
overall mortality was 65% (TH 58.3% vs. IMP 75%, p¼0.64). Table outlines
in-hospital outcomes.
Conclusions: In this small patient cohort we found no signiﬁcant difference between
IMP and TH for the treatment of RCS. Vascular, neurological and rhythm related
complications were similar. Overall mortality remains high in patients with RCS
despite TH and IMP support. Prospective trials and comparative studies of TH and
IMP in patients with RCS are needed before a recommendation for use is made.In-hospital outcomesComplications All n (%) Impella® n (%)
Tandem
Heart® n (%) p valueArrhythmia 8 (40.0) 3(37.50) 5(41.67) 1.0Vascular Repair 1(5.0) 0(0) 1(8.33) 1.0Acute Limb Ischemia 2(10.0) 1(12.50) 1(8.33) 1.0Hematoma 1(5.0) 0(0) 1(8.33) 1.0Acute Renal Failure 16(80.0) 7(87.50) 9(75.0) 0.62GI Bleed 1(5.0) 0(0) 1(8.33) 1.0Stroke 2(10.0) 1(12.50) 1(8.33) 1.0Death 13(65.0) 6(75.0) 7(58.33) 0.64ENDOVASCULAR-Renal Intervention
CRT-217
Long Term Safety and Efficacy of a Multi-electrode Renal Artery Denervation Catheter
in Patients with Drug-Resistant Hypertension: Twelve and 18 Month Results of a
First-in-Human, Multicenter Study
Vasilios Papademetriou,1 Costas Tsiouﬁs,1 Stephen Worthley2
1Georgetown University, Potomac, MD; 2Monash, Adelaide, Austria
Background: Recent estimates indicate that 8-12% of patients with hypertension do
not respond adequately to optimal medical therapy. Sympathetic renal artery
denervation is emerging as a viable treatment option for patients with drug resistant
HTN but long-term results using multi-electrode ablations systems have not been
reported.
Methods and Results: The EnligHTN renal denervation system (St Jude Medical)
has 4 electrodes attached on a basket mounted at the tip of the catheter and can deliver
multiple transmural lesions in a predetermined pattern. The EnligHTN-I ﬁrst-
in-human study was designed to assess the safety and efﬁcacy of this multi-electrode
ablation system in patients with drug-resistant hypertension. A total of 46 pts (av. age
6010yrs, on 4.80.6 meds) were enrolled. Of these pts 33% were female, 98% were
white, 20% had Coronary Artery Disease, 59% had hyperlipidemia, 33% had type II
Diabetes Mellitus, and 30% had history of sleep apnea. On average 7.70.8 lesions
were created in the right renal artery and 7.41.4 in the left. Baseline av. ofﬁce BP was
176/96 mmHg and average 24 hr ambulatory BP 150/83 mmHg. Average reductions
(mmHg) of ofﬁce BP at 1, 3, 6 and 12 months were -28/10, -27/10, -26/10 and -27/
11 mmHg (p<0.001) respectively and for 24hr ambulatory BP -10/5, -10/5 and -10/
6 mmHg (p<0.001) data for 12 month N/A. At 12 months 80% of patients were
responders, 75% had ofﬁce BP <160 systolic and 29% had normalized BP. At
6 months there was a small reduction in the estimated glomerular ﬁltration rate (from
87 to 82 mL/min/1.73m2) driven by a small increase in serum creatinine from 78 to
83 mmol/L), but both values returned to baseline at 12 months. Cystatin C levels and
microalbuminuria improved signiﬁcantly up to 12 months. There were 3 device/pro-
cedure related serious adverse events reported to date: hypertensive renal disease
progression, symptomatic hypotension and worsening of pre-existing renal artery
stenosis. Eighteen month efﬁcacy and safety data will be available to be presented at
the meeting.
Conclusions: We conclude that data demonstrates that the EnligHTN ablation
system continues to be safe and effective in the treatment of patients with drug-
resistant hypertension.TECHNOLOGY-Renal Denervation
CRT-609
Renal Denervation Using Standard 5F Radiofrequency Ablation Catheter in Patients
with End Stage Renal Disease: A 6 Month Follow-Up
Amitabh Yaduvanshi, Sanjib Patra, Sanjeev Gupta, Mohan Nair
Saket City Hospital, New Delhi, India
Background: Renal denervation has been proven to be beneﬁcial in treating resistant
hypertension in patients with normal renal function. There are a signiﬁcant number of
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Nend stage renal disease (ESRD) patients who have resistant hypertension despite being
on multiple drugs and the beneﬁts of RDN in such patients have not been reported.
Renal denervation has been studied using proprietary catheters but the same procedure
can be done by conventional catheters. The use of additional mapping and imaging
techniques can help in precise localization of the RF lesions.
Methods: We report use of standard 4mm tip 5F RF catheters with conventional
RF generators to give RF lesion to renal arteries using rotational angiography and
3D electroanatomical mapping to plan and guide the placement of these lesions in
9 patients with ESRD and uncontrolled hypertension.
Results: There was a signiﬁcant drop in blood pressure in all the patients 26.8 
13.5 mmHg in systolic and 14.8  6.7 mmHg fall in diastolic BP at 1week follow up
and 38.0  12.12 mmHg systolic, 19.3  7.21 mmHg fall in diastolic BP at 1 month
follow up. The drop in blood pressure was persistent and was 41.8  16.3 mmHg in
systolic and 20.4  9.7 mmHg fall in diastolic BP at 6month follow up as compared to
baseline. There were no peri-procedural complications.
Conclusions: The use of conventional RF catheters for renal denervation is feasible
and effective. Renal denervation in ESRD patients is as effective in controlling hy-
pertension as in patients without renal failure. The use of additional mapping and
imaging modalities helps in more precise location of the lesions and may increase the
safety of the procedure.VALVE & STRUCTURAL HEART-Aortic Valve
CRT-713
Usefulness of a Novel Index in Predicting the Permanent Pacemaker Necessity
Following Transcatheter Aortic Valve Replacement
Marco A. Magalhaes, Sa`ar Minha, Jose F. Rodriguez-Weisson, Ricardo O. Escarcega,
Nevin C. Baker, Petros Okubagzi, Rebecca Torguson, Fang Chen, Pendyala Lakshmana,
Joshua P. Loh, Omar Al Fazir, Ota Hideaki, Tian Wenjie, Zuyue Wang,
Steven A. Goldstein, Itsik Ben-Dor, William O. Suddath, Lowell F. Satler,
Augusto D. Pichard, Ron Waksman
MedStar Heart Institute, Washington, DC
Background: Permanent Pacemaker implantation (PP) following Transcatheter
Aortic Valve Replacement (TAVR) is associated with increased morbidity and costs.
However, PP predictors have been scarcely investigated.
Methods: We retrospectively analyzed data from a cohort of symptomatic aortic
stenosis patients who underwent TAVR and had 2-dimension echocardiogram derived
left ventricular outﬂow tract (LVOT) diameter available. The exclusion criteria were:
prior pacemaker and more than 1 valve implanted. We calculated the index as: [valve
size (VS)/LVOT]*100. Receiver-operating curve (ROC) was used to determine the
binary cut-off value. Variables were selected from univariate analysis and adjusted in
the logistic regression model.
Results: The study cohort consisted of 450 consecutive patients. From those, 17%
had a prior PPM and 9 received more than 1 valve. ROC analysis demonstrated the
best cut-off value of 129 for VS/LVOT index (sensitivity¼71%, speciﬁcity¼67%) to
predict PP (C-Statistic¼0.74; ﬁgure). VS/LVOT index as a function of PP probability
is depicted (ﬁgure). The adjusted determinants of PP following TAVR were: atrial
ﬁbrillation (odds ratio (OR): 4.8 [95% Conﬁdence Interval [CI]: 1.6-11.3; p<0.01),
left bundle branch block (OR: 2.7 [1.0-7.4]; p<0.05) and VS/LVOT of 129 (OR: 3.5
[1.3-9.3]; p<0.01).
Conclusions: A simple and non-invasive index of valve size and the left ventricular
outﬂow tract independently predicts the PP requirement following TAVR with good
accuracy. Further validation and incorporation in the clinical practice may improve the
valve selection size and decrease the PP incidence.
